You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

54 search results for: asthma

Airway Remodeling in Type 2 <b>Asthma</b> is Driven by IL-4 and IL-13

expert video

Airway Remodeling in Type 2 Asthma is Driven by IL-4 and IL-13

24 min

Pulmonology

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

FeNO: A Biomarker of Type 2 Inflammation in Pediatric <b>Asthma</b> Patients

Infographic

FeNO: A Biomarker of Type 2 Inflammation in Pediatric Asthma Patients

5 min

Pulmonology

Learn about the role of FeNO as a noninvasive test to identify type 2 inflammation in pediatric patients with asthma

Why Is It Important to Assess Lung Function in Pediatric <b>Asthma</b>

interactivity

Why Is It Important to Assess Lung Function in Pediatric Asthma

5 min

Pulmonology

Learn about FEV1pp and the downstream effects of lung function decline in children with severe asthma

Pediatric <b>Asthma</b> Patient Case Tool: Ash

interactivity

Pediatric Asthma Patient Case Tool: Ash

5 min

Pulmonology

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

The Cycle of Inflammation in Adult <b>Asthma</b>

interactivity

The Cycle of Inflammation in Adult Asthma

5 min

Pulmonology

Explore the role of chronic type 2 inflammation in the cycle of exacerbations and worsening lung function in asthma patients

videoanimation

Type 2 Inflammation and Airway Remodeling Drive Lung Function Decline

4 min

Pulmonology

Explore the impact of type 2 inflammation and airway remodeling on lung function decline in asthma.

COPD and <b>Asthma</b>: What's the Difference and Is There a Link?

interactivity

COPD and Asthma: What's the Difference and Is There a Link?

5 min

Pulmonology

Explore the characteristics of COPD and asthma, focusing on their shared inflammatory mechanisms and key clinical differences.

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe <b>Asthma</b>

expert video

ERS 2024 | Pathophysiologic Mechanisms of Airway Remodeling in Severe Asthma

15 min

Pulmonology

Professor Celeste Porsbjerg presents the pathophysiology and disease processes involved in airway remodeling in severe asthma.

expert video

ERS 2024 | Airway Remodeling: A Permanent or Transitory Consequence in Severe Asthma Patients?

78 min

Pulmonology

Professors Celeste Porsbjerg and Klaus Rabe and Dr Mario Castro discuss the pathophysiology of airway remodeling and its impact on patients with severe asthma.

ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe <b>Asthma</b>

Podcast

ADVENT On Air | Diving Deep: Exploring the Impact of Airway Remodeling in Severe Asthma

20 min

Pulmonology

Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma.

What Differentiates COPD Exacerbations From <b>Asthma</b> Exacerbations?

expert video

What Differentiates COPD Exacerbations From Asthma Exacerbations?

2 min

Pulmonology

Join global expert Dr. Eric Bateman as he discusses how exacerbations in patients with COPD are different than exacerbations in patients with asthma.

expert video

EAACI 2024 On-Treatment Clinical Remission in Upper and Lower Airways: Going Beyond Symptom Control

29 min

Pulmonology

Join global experts for an educational symposium on elevating treatment goals from control to remission in the upper and lower airways.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: EcuadorChange country/region